In this pilot randomized study, the authors therefore compared the effects of 24-weeks of pemafibrate at the 0.2mg dose with an ILI comprised of energy restriction plus exercise designed to induce ∼5 % weight loss on hepatic steatosis and stiffness measured by FibroScan (a transient elastography), serum liver enzymes, and serum sDPP-4/CD26 in people with type 2 diabetes and MASLD. The gene discussed is DPP4; the disease is fatty liver disease.